Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260049 | 0.94 | TSHR (0.53) | TSHRHSD17B10KCNJ1KCNH2LOXL2 | |
| SCHEMBL9864668 | 0.93 | TSHR (0.56) | TSHRHSD17B10KCNJ1KCNH2LOXL2 | |
| SCHEMBL2246626 | 0.88 | KCNJ1 (0.48) | TSHRHSD17B10KCNJ1KCNH2LOXL2 | |
| SCHEMBL20212772 | 0.88 | TSHR (0.64) | TSHRHSD17B10KCNJ1KCNH2LOXL2 | |
| SCHEMBL9457792 | 0.83 | TSHR (0.53) | TSHRHSD17B10KCNJ1KCNH2LOXL2 | |
| SCHEMBL27707611 | 0.82 | FFAR1 (0.36) | TSHRHSD17B10 | |
| SCHEMBL9640908 | 0.81 | TSHR (0.62) | TSHRHSD17B10KCNJ1KCNH2LOXL2 | |
| SCHEMBL10569888 | 0.81 | TSHR (0.68) | TSHRHSD17B10KCNJ1KCNH2LOXL2 | |
| SCHEMBL4826285 | 0.81 | TSHR (0.54) | TSHRHSD17B10KCNJ1KCNH2LOXL2 | |
| SCHEMBL9458406 | 0.81 | TSHR (0.50) | TSHRHSD17B10KCNJ1KCNH2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3147278-B1 | COMPOUND FOR TREATING BREAST CANCER AND PROGESTIN-DEPENDENT CONDITIONS | UNIV TENNESSEE RES FOUND (US) | 2020-02-12 | — | — | EP | disclosed |
| US-8420685-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2013-04-16 | — | — | US | disclosed |
| US-20080319022-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2008-12-25 | — | — | US | disclosed |
| US-7407958-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2008-08-05 | — | — | US | disclosed |
| EP-1620426-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | In2gen Co., Ltd. (KR) | 2006-02-01 | — | — | EP | disclosed |
| US-20050261299-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2005-11-24 | — | — | US | disclosed |
| WO-2005103028-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | IN2GEN CO., LTD (KR) | 2005-11-03 | — | — | WO | disclosed |
| US-5238602-A | Electrooptical cells | HOFFMANN LA ROCHE INC. (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0168683-B1 | LIQUID CRYSTALS WITH ALKENYL OR ALKENYLOXY GROUPS | F. HOFFMANN-LA ROCHE AG (CH) | 1990-11-28 | — | — | EP | disclosed |
| EP-0167912-B1 | LIQUID CRYSTAL MIXTURES CONTAINING COMPOUNDS WITH A 4-ALKENYL OR 2Z-ALKENYL LATERAL CHAIN | F. HOFFMANN-LA ROCHE AG (CH) | 1990-01-03 | — | — | EP | disclosed |
| US-4709030-A | 4-ALKENYL OR 2Z-ALKENYL POLYPHENYL COMPOUNDS; ELECTRO-OPTICS | HOFFMANN-LA ROCHE INC. (US) | 1987-11-24 | — | — | US | disclosed |
| US-4621901-A | ELECTROOPTICS | HOFFMANN-LA ROCHE INC. (US) | 1986-11-11 | — | — | US | disclosed |
| EP-0168683-A2 | Liquid crystals with alkenyl or alkenyloxy groups | F. HOFFMANN-LA ROCHE AG (CH) | 1986-01-22 | — | — | EP | disclosed |
| EP-0167912-A2 | Liquid crystal mixtures containing compounds with a 4-alkenyl or 2Z-alkenyl lateral chain | F. HOFFMANN-LA ROCHE AG (CH) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261299-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | ACVR1, ACVRL1, ACVR1B | TSHR 407/4885HSD17B10 3513/4885KCNJ1 3346/4885 |
| US-20080319022-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | ALK, ERBB4, ACVR1 | TSHR 605/4885HSD17B10 4042/4885KCNJ1 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.